Glutamate modulators for treatment of schizophrenia
| Autor: | Philip D. Harvey, Naista Zhand, David G. Attwood |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Psychosis
business.industry Schizophrenia (object-oriented programming) Glutamate receptor Glutamatergic Agents medicine.disease behavioral disciplines and activities 030227 psychiatry 03 medical and health sciences Psychiatry and Mental health Clinical Psychology Glutamatergic 0302 clinical medicine mental disorders NMDA receptor Medicine Neurology (clinical) business Neuroscience 030217 neurology & neurosurgery Schizophrenia spectrum |
| Zdroj: | Personalized Medicine in Psychiatry. :1-12 |
| ISSN: | 2468-1717 |
| DOI: | 10.1016/j.pmip.2019.02.001 |
| Popis: | Over the past two decades, accumulating evidence has implicated the role of glutamatergic dysfunction in the pathophysiology of schizophrenia. There has been growing interest in glutamatergic system as a promising target for treatment of schizophrenia spectrum illness and several medications and compounds have been investigated to date. In the present study, we aim to provide a comprehensive review of clinical studies of glutamatergic agents in treatment of schizophrenia. We further discuss the heterogeneity of the results, the overall discouraging outcomes and future directions for investigating glutamatergic medications in schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect